Literature DB >> 10917069

Prospects for vaccination in prostate cancer.

M J Perry1, D Hroulda, A G Dalgleish.   

Abstract

Prostate cancer continues to be a major cause of morbidity and mortality. Surgical and medical management of the disease has improved but there is little effect upon overall survival. Novel therapies such as immunotherapy offer the potential of treating the disease by stimulating the immune system to mount a response to the cancer systemically. This review highlights the pitfalls and progress in the understanding of the role of the immune system in malignancy and also explains the theory behind prostate cancer vaccine trials.

Entities:  

Mesh：

Year:  2000        PMID： 10917069     DOI： 10.2165/00002512-200016050-00001

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


  55 in total

1.  Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine.

Authors:  M C Thomas; T F Greten; D M Pardoll; E M Jaffee
Journal:  Hum Gene Ther       Date:  1998-04-10       Impact factor: 5.695

2.  Enhancement of tumor killing using a combination of tumor immunization and HSV-tk suicide gene therapy.

Authors:  R Ramesh; A Munshi; A J Marrogi; S M Freeman
Journal:  Int J Cancer       Date:  1999-01-29       Impact factor: 7.396

3.  Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis.

Authors:  P T Daniel; A Kroidl; S Cayeux; R Bargou; T Blankenstein; B Dörken
Journal:  J Immunol       Date:  1997-10-15       Impact factor: 5.422

4.  Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts.

Authors:  A Mackensen; H Veelken; M Lahn; S Wittnebel; D Becker; G Köhler; P Kulmburg; U Brennscheidt; F Rosenthal; B Franke; R Mertelsmann; A Lindemann
Journal:  J Mol Med (Berl)       Date:  1997-04       Impact factor: 4.599

5.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.

Authors:  F L Moolten
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

6.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

7.  Demonstration of a rational strategy for human prostate cancer gene therapy.

Authors:  M G Sanda; S R Ayyagari; E M Jaffee; J I Epstein; S L Clift; L K Cohen; G Dranoff; D M Pardoll; R C Mulligan; J W Simons
Journal:  J Urol       Date:  1994-03       Impact factor: 7.450

8.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

Authors:  S M Freeman; C N Abboud; K A Whartenby; C H Packman; D S Koeplin; F L Moolten; G N Abraham
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

9.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.

Authors:  R Soiffer; T Lynch; M Mihm; K Jung; C Rhuda; J C Schmollinger; F S Hodi; L Liebster; P Lam; S Mentzer; S Singer; K K Tanabe; A B Cosimi; R Duda; A Sober; A Bhan; J Daley; D Neuberg; G Parry; J Rokovich; L Richards; J Drayer; A Berns; S Clift; L K Cohen; R C Mulligan; G Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

10.  Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer.

Authors:  P Guinan; E Toronchi; M Shaw; R Crispin; R Sharifi
Journal:  Urology       Date:  1982-10       Impact factor: 2.649
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.